@article{a9e75f4620394ba1af336a5f35ab3cd8,
title = "Physician and Patient Satisfaction with Poly(ADP-ribose) Polymerase Inhibitors (PARPi) versus Chemotherapy in Adult Patients with Germline BRCA1/2 Mutated (gBRCA1/2mut) HER2- advanced Breast Cancer (ABC): Results from a Multi-country Real-world (RW) Study",
abstract = " M. Lux; A. Niyazov; K. Lewis; J. Pike; A. Rider; B. Arondekar ",
author = "Reshma Mahtani",
note = "Abstract. Background: Within the past 3 years, PARPi have demonstrated improved progression-free survival and favorable PROs compared with chemotherapy in randomized clinical trials in patients with gBRCA1/2mut HER2- ABC. These agents are now available in multiple countries for the treatment of gBRCA1/2mut HER2- locally advanced and/or metastatic breast cancer.",
year = "2021",
month = feb,
day = "15",
language = "American English",
volume = "81",
journal = "Cancer Research / San Antonio Breast Cancer Symposium",
}